POLPHARMA-BIOLOGICS
6.8.2021 11:16:07 CEST | Business Wire | Press release
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis® ).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis® .
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veracode 2026 State of Software Security Report Reveals Four Out of Five Organizations Are Drowning in Security Debt24.2.2026 13:50:00 CET | Press release
High-Risk Vulnerabilities Spike 36% Year-Over-Year as Critical Security Debt Surges 20%, Signaling a Growing Crisis in Software Security Veracode, the global leader in application risk management, today released its 2026 State of Software Security Report, revealing the widening gap between how fast organizations build software and how fast they can secure it. The report found 82 percent of organizations now harbor security debt—an 11 percent increase from the prior year—and that 60 percent of those organizations have security debt defined as “critical,” representing accumulated vulnerabilities severe enough to cause catastrophic damage to an organization if exploited. The report recommends adopting a “Protect, Prioritize, and Prove” strategy to meaningfully reduce risk in 2026 and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224526703/en/ Fig. 1: Veracode State of Software Security Report 2025 vs 2026 YoY Change
Canoga Perkins and Druid Deliver FRER-Enabled Resilience for Mission-Critical Private 5G Networks24.2.2026 13:00:00 CET | Press release
Canoga Perkins and Druid Software showcased their partnership with Canoga Perkins demonstrating Frame Replication and Elimination for Reliability (FRER) at the Winter 2025 Druid Demo Days. This marks a new era of networking for mission critical applications across industries such as mining, industrial automation, and smart manufacturing. FRER is the foremost data protection mechanism delivering unmatched, lossless delivery of mission critical data. Canoga Perkins and Druid created a Private 5G network where SyncMetra protected traffic between the Druid’s Raemis core and the Radio Area Network delivering hitless failover and continuous video traffic. Canoga Perkins is pleased to announce their return to MWC Barcelona in 2026, where they will once again showcase their advanced technical demonstration highlighting FRER and cutting‑edge 5G TSN solutions. The Canoga Perkins team will be on-site to discuss the latest advancements in deterministic networking, including Frame Replication and E
Quantum XChange Advances EUCC Milestone and Enterprise Scalability with Latest Release of Phio TX24.2.2026 13:00:00 CET | Press release
New EUCC Compliance Mode and Enhanced Hive Architecture Strengthen Security for Regulated European and Global Networks Quantum XChange today announced the latest release of its cryptographic management platform Phio TX® which introduces a new European Union Cybersecurity Certification (EUCC) compliance mode and significant enhancements to its Hive architecture to support massive-scale, distributed deployments. The release marks a critical milestone toward full EUCC validation for Phio TX and reinforces the company’s commitment to meeting rigorous international security standards for customers operating in regulated European markets. EUCC is a European Union–wide certification framework based on Common Criteria (ISO/IEC 15408), providing independent evaluation of Information and Communications Technology (ICT) products against high EU cybersecurity standards. Similar in importance to FIPS validation in the United States, EUCC validation is increasingly critical for organizations handlin
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 202624.2.2026 12:39:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through
Simon-Kucher Selects Navan to Modernize Global Travel Program24.2.2026 11:00:00 CET | Press release
Global consultancy to consolidate travel operations with Navan across more than a dozen markets Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Simon-Kucher, the world’s leading commercial growth and pricing consultancy, as its global travel partner. Simon-Kucher teams will now have access to Navan’s AI-powered travel management platform across more than a dozen markets, including in the North American, European, and APAC regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224745907/en/ Simon-Kucher Selects Navan to Modernize Global Travel Program “Our work is increasingly global, and travel remains essential to how we collaborate with clients and with one another,” said Thomas Wohlan, Director of Travel Management at Simon-Kucher. “To support that at scale, we needed a modern travel platform that brings consistency across countries and simplifi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom